Astria Therapeutics, Inc.

NASDAQ:ATXS

11.54 (USD) • At close November 4, 2024
Bedrijfsnaam Astria Therapeutics, Inc.
Symbool ATXS
Munteenheid USD
Prijs 11.54
Beurswaarde 651,147,962
Dividendpercentage 0%
52-weken bereik 4.26 - 16.9
Industrie Biotechnology
Sector Healthcare
CEO Ms. Jill C. Milne Ph.D.
Website https://www.astriatx.com

An error occurred while fetching data.

Over Astria Therapeutics, Inc.

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of

Vergelijkbare Aandelen

Zynerba Pharmaceuticals, Inc. logo

Zynerba Pharmaceuticals, Inc.

ZYNE

1.3 USD

Acasti Pharma Inc. logo

Acasti Pharma Inc.

ACST

3.37 USD

NexImmune, Inc. logo

NexImmune, Inc.

NEXI

0.218 USD

Aquestive Therapeutics, Inc. logo

Aquestive Therapeutics, Inc.

AQST

5.15 USD

Ocuphire Pharma, Inc. logo

Ocuphire Pharma, Inc.

OCUP

1.17 USD

Eledon Pharmaceuticals, Inc. logo

Eledon Pharmaceuticals, Inc.

ELDN

4.83 USD

Eargo, Inc. logo

Eargo, Inc.

EAR

2.57 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)